Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Neurocrine Biosciences Inc (NBIX) vs Valero Energy Corporation (VLO) Price & Performance

Neurocrine Biosciences IncTrade
Valero Energy CorporationTrade

Price performance (Past 24H)

Key statistics

Neurocrine Biosciences Inc vs Valero Energy Corporation — how do they compare? Neurocrine Biosciences Inc trades at $156.06 (market cap $16.46B), while Valero Energy Corporation trades at $331.25 (market cap $93.27B). The key difference: Valero Energy Corporation is far larger — about 5.7× Neurocrine Biosciences Inc's market cap, and Valero Energy Corporation pays a 1.48% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.

NBIXVLO
Market Cap
$16.46B$93.27B
Sector
HealthEnergy
52-Week High
$185.50$323.92
52-Week Low
$123.10$133.38
Enterprise Value
$16.48B$96.74B
Dividend Yield
1.48%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $156.49, down 5.11% amid bearish technical signals despite strong fundamentals. The stock shows robust revenue growth with Q2 2026 sales up 39% year-over-year to $959 million, beating earnings estimates. Recent news highlights pipeline advancement with a Phase 1 GLP-1/GIP/glucagon agonist study initiation while facing safety concerns for Vykat XR in Prader-Willi syndrome.

Outlook remains positive with 86% analyst buy ratings and $208.82 consensus target offering 33% upside. Key risks include drug safety scrutiny and execution on pipeline catalysts. Strong institutional interest persists with CalPERS increasing holdings by 13% in Q2 2026, supporting long-term growth narrative amid near-term technical weakness.

Valero Energy Corporation

Valero Energy (VLO) trades at $329.99, up 4.78% on the day, reflecting strong momentum after recent earnings beats. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals indicate robust profitability with a 29.31% ROE and a P/E of 13.51. Recent news highlights refining strength and geopolitical factors benefiting the sector.

Outlook remains positive with analyst consensus favoring a Buy rating and a $324.27 price target. Key risks include volatile oil prices and refining margin pressures, but disciplined capital allocation and renewable diesel growth offer upside potential for investors seeking energy exposure.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX

About Valero Energy Corporation

Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.

Read more on VLO